Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.


INTRODUCTION Cognitive deficits are a prominent, disabling component of schizophrenia and current pharmacological treatments have demonstrated limited efficacy in their amelioration. Oxytocin - though it has shown promise as a novel antipsychotic in multiple clinical trials - has as-yet poorly characterized effects on cognition, with some evidence… (More)
DOI: 10.1016/j.schres.2012.05.018